Endonovo Therapeutics (Endonovo Therapeutics) EV-to-EBITDA : 0.85 (As of May. 27, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Endonovo Therapeutics's enterprise value is $7.53 Mil. Endonovo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $8.85 Mil. Therefore, Endonovo Therapeutics's EV-to-EBITDA for today is 0.85.

The historical rank and industry rank for Endonovo Therapeutics's EV-to-EBITDA or its related term are showing as below:

ENDV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -156.27 Med: -4.02 Max: 19.08
Current: 0.85

During the past 13 years, the highest EV-to-EBITDA of Endonovo Therapeutics was 19.08. The lowest was -156.27. And the median was -4.02.

ENDV's EV-to-EBITDA is ranked better than
72.22% of 450 companies
in the Biotechnology industry
Industry Median: 9.57 vs ENDV: 0.85

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Endonovo Therapeutics's stock price is $0.0013. Endonovo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.005. Therefore, Endonovo Therapeutics's PE Ratio for today is 0.26.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Endonovo Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Endonovo Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics EV-to-EBITDA Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-0.86

3.04

-5.45

-0.67

1.11

Endonovo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-0.67	-1.65	-4.75	-4.36	1.11

Competitive Comparison of Endonovo Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Endonovo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's EV-to-EBITDA falls into.

Endonovo Therapeutics EV-to-EBITDA Calculation

Endonovo Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	7.525	/	8.853
	=	0.85

Endonovo Therapeutics's current Enterprise Value is $7.53 Mil.
Endonovo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.85 Mil.

Endonovo Therapeutics (OTCPK:ENDV) EV-to-EBITDA Explanation

Endonovo Therapeutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.0013	/	0.005
	=	0.26

Endonovo Therapeutics's share price for today is $0.0013.
Endonovo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.005.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Endonovo Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367